Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong

Journal of Gastroenterology and Hepatology (Australia)

Volumn 32, Issue 6, 2017, Pages 1230-1233

  Chan, Henry Lik Yuen ^a   Tsang, Owen Tak Yin ^b   Hui, Yee Tak ^c   Fung, James ^d   Lui, Grace Chung Yan ^a   Lai, Ching Lung ^d   Wong, Grace Lai Hung ^a   Chan, Kam Hon ^e   But, David Yiu Kuen ^d   Lai, Moon Sing ^e   Lao, Wai Cheung ^f   Chan, Carmen Ka Man ^a   Lam, Yip Shun ^c   Seto, Wai Kay ^d   Li, Carlton ^c   Yuen, Man Fung ^d   Wong, Vincent Wai Sun ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b PRINCESS MARGARET HOSPITAL   (Hong Kong)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e NORTH DISTRICT HOSPITAL   (Hong Kong)

^f PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

Author keywords

antiviral treatment; hepatitis C; real life; ribavirin

Indexed keywords

DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PEGINTERFERON; RIBAVIRIN; VIRUS RNA; ABT-267; ABT-333; ABT-450; ANILIDE; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; MACROCYCLIC COMPOUND; RITONAVIR; SULFONAMIDE; URACIL;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CELLULITIS; CHRONIC HEPATITIS C; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; COMPENSATED LIVER CIRRHOSIS; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HONG KONG; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALAISE; MALE; MIDDLE AGED; MIXED INFECTION; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; PRURITUS; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; VOMITING; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; GENETICS; GENOTYPE; HEPACIVIRUS; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY;

ANILIDES; ANTIVIRAL AGENTS; CARBAMATES; COINFECTION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HONG KONG; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MACROCYCLIC COMPOUNDS; RETROSPECTIVE STUDIES; RIBAVIRIN; RITONAVIR; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; URACIL;

EID: 85020086374     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13663     Document Type: Article

References (15)

1. Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus. J. Hepatol. 2015; 62: S87–99.
2. Yan KK, Wong GL, Wong VW, Chan HL. Rate and factors affecting treatment uptake of patients with chronic hepatitis C in a tertiary referral hospital. Dig. Dis. Sci. 2010; 55: 3541–3547.
3. Ferenci P, Bernstein D, Lalezari J et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N. Engl. J. Med. 2014; 370: 1983–1992.
4. Poordad F, Hezode C, Trinh R et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N. Engl. J. Med. 2014; 370: 1973–1982.
5. Andreone P, Colombo MG, Enejosa JV et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147: 359–365.
6. Feld JJ, Moreno C, Trinh R et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. J. Hepatol. 2016; 64: 301–307.
7. AbbVie received U.S. FDA approval of supplemental new drug application for VIEKIRA PAK (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets) without ribavirin in genotype 1b chronic hepatitis C patients with compensated cirrhosis. April 25, 2016. (https://news.abbvie.com/news/abbvie-receives-us-fda-approval-supplemental-new-drug-application-for-viekira-pak-ombitasvir-paritaprevir-and-ritonavir-tablets-dasabuvir-tablets-without-ribavirin-in-genotype-1b-chronic-hepatitis-c-patients-with-compensated-cirrhosis.htm).
8. Hezode C, Fontaine H, Dorival C et al. Effectiveness of Telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147: 132–142.
9. Ioannou GN, Beste LA, Chang MF et al. Effectiveness of Sofosbuvir, ledipasvir/Sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the veterans affairs national health care system. Gastroenterology 2016; 151: 457–471.
10. Hinrichsen H, Wedemeyer H, Christensen S et al. Real-world safety and effectiveness of ombitasvir/paritaprevir/R with dasabuvir and/or ribavirin in the German hepatitis C registry. J. Hepatol. 2016; 64: S159.
11. Zuckerman E, Ashkenasi E, Kovalev Y et al. The real-world Israeli experience of treating chronic hepatitis C, genotype 1 patients with advanced fibrosis with paritaprevir/ritonavir/ombitasvir and dasabuvir with or without ribavirin: a large multi-center cohort. J. Hepatol. 2016; 64: S137.
12. Backus LI, Belperio PS, Shahoumian TA, Loomis T, Mole L. Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin and ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6,961 genotype 1 patients treated in routine medical practice. Gastroenterology 2016; 150: S1036.
13. Tsang OT, Zee JS, Cahn JM et al. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1. J. Gastroenterol. Hepatol. 2010; 25: 766–771.
14. Lai CL, Wong VW, Yuen MF et al. Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong. Aliment. Pharmacol. Ther. 2016; 43: 96–101.
15. Chan HL, Li PK. Chronic kidney disease: treatment of hepatitis C virus infection with CKD. Nat. Rev. Nephrol. 2016; 12: 5–6.